Two patients diagnosed with advanced head and neck cancer were treated with cetuximab 400 mg/m2 intravenously for one loading dose followed by 250 mg/m2 IV on days 1, 8, and 15 along with paclitaxel 80 mg/m2 and cisplatin 30 mg/m2 intravenously on days 1 and 8 repeated every 21 days for three cycles (CPP). Maintenance cetuximab 250 mg/m2 intravenously weekly was continued following the aforementioned regimen for one year or until disease progression. Patient A was diagnosed with squamous cell carcinoma of the parotid gland treated initially with parotidectomy and radiation therapy. After the detection of multiple lung metastases, he received three cycles of CPP and maintained a stable disease after one year. Patient B was diagnosed with metastatic laryngeal cancer and was initially treated with three cycles of docetaxel, cisplatin, and continuous infusion fluorouracil (TPF) followed by chemoradiation with cisplatin. After one year, recurrence was observed, and she was treated with laryngopharyngectomy. After another year, recurrence was observed , and CPP was initiated. Further progression was noted shortly after completion of cycle 3. There are limited data supporting the use of regimens similar to CPP in advanced head and neck cancer. Further study is needed to determine the relative efficacy and safety of CPP compared with other regimens containing monoclonal antibodies targeting the epidermal growth factor receptor, taxanes, platinum agents, and/or fluorouracil.
| 1. | Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8–14. Google Scholar CrossRef, Medline |
| 2. | Rangaraju RR, Sharma JB, Dewan AK, et al. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis. Indian J Cancer 2012; 49: 1–5. Google Scholar CrossRef, Medline |
| 3. | Bauman J, Langer C, Quon H, et al. Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. Exp Ther Med 2013; 5: 1247–1253. Google Scholar Medline |
| 4. | Narveson L, Kathol E, Rockey M, et al. Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Med Oncol 2016; 33: 107–107. Google ScholarCrossRef, Medline |
| 5. | Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). J Clin Oncol 2016; 34(supp): abstr 6026–abstr 6026.Google Scholar |
| 6. | Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 13–21. Google Scholar CrossRef, Medline |
| 7. | Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409–422. Google Scholar CrossRef, Medline |
| 8. | Guan J, Li Q, Zhang Y, et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget 2016; 7: 7110–7119. Google Scholar CrossRef, Medline |
| 9. | Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646–8654. Google Scholar CrossRef, Medline |
| 10. | Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116–1127. Google Scholar CrossRef, Medline |
| 11. | Bossi P, Kornek G, Lanzetta G, et al. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck 2013; 35: 1471–1474. Google Scholar Medline |
http://ift.tt/2vmFIbu
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου